15 October - 18 October 2019

Meet us at the Immunogenicity & Bioassays Summit

Let´s talk Gene Therapy at the 2019 Immunogenicity & Bioassays Summit in Washington, DC

Join us in Washington for the exciting opportunity to learn from the Svar team; Camilla Duborn, Dr. Michael Schwenkert, Therese Segerstein and our speaker Dr Michael Tovey, as they discuss how the products we're developing and the services we offer to help address the obstacles and analytical challenges involved in Gene Therapy.  Stop by Booth 13 and join us over a Swedish Fika and get the chance to win a Swedish designer backpack!

If you'd like to know more about how our iLite® cell-based assay technology and Bioanalytical Services can help accelerate your drug development? Make sure you book a meeting in advance and don't miss our podium presentation with Dr Michael Tovey on 16th of October at 11.40am.

Book a meeting

We are very proud to be hosting a podium presentation on the exciting topic of "Development of an iLite® Reporter cell line for the quantification of anti-AAV neutralizing antibodies.”

INVITATION-Gene-Therapy-M-Tovey-Presentation-2019"The efficacy of adeno-associated virus (AAV) mediated gene-therapy is limited by the development of anti-AAV antibody-mediated immunity against the virus capsid proteins resulting from previous exposure, often in early childhood, to one or more AAV serotypes. The prevalence of anti-AAV antibodies in a normal population was found to be highest for AAV1 and AAV2, approximately 67 % and 72% respectively, and 38% and 47% for AAV8 and AAV9 respectively. Furthermore, due to the high degree of conservation of the amino acid sequence of the capsid proteins, anti-AAV antibodies exhibit a high degree of cross-reactivity among different AAV serotypes, and even low-titer neutralizing antibodies (NAbs) can completely neutralize the recombinant virus. Indeed, an inverse relationship between the efficacy of AAV based gene-therapy and the development of neutralizing anti-AAV antibodies has been observed in several clinical studies.

Thus, it is of considerable importance to develop sensitive and precise cell-based in vitro assays suitable for the quantification of anti-AAV Nabs in a clinical environment. Reporter assays based on the establishment of a cell line stably transfected with a luciferase reporter-gene placed under the control of a signal specific responsive chimeric promoter, provide highly sensitive and precise methods for quantifying the activity of a wide range of biologically active agents. We have shown previously that such methods also provide the basis for the establishment of highly sensitive and precise cell-based assays for the quantification of the neutralizing antibody response to numerous pharmacology active agents.

We have also shown that, normalization of reporter gene activity induced by the factor of interest, relative to the expression of an internal standardization gene renders assay results independent of cell number and provides a means for correcting for serum matrix effects.

The availability of reporter cells in a frozen, thaw & use format, obviates the need for cell culture or specialized equipment and provides a means for obtaining highly reproducible results superior to those obtained using the same cells maintained in culture. An assay for the quantification of anti-AAV neutralizing antibodies will be described that reflects the effect of anti-AAV Nabs on the expression of recombinant AAV vectors."


Join us as we explore the future of Gene Therapy and find out how we can help streamline your future projects!

#ImmunoBio19 #svarlifescience #wieslab #bioanalyticalservices #laboratoryservices #cellbasedassays #ilite #bioanalytical #drugdevelopment #genetherapy #development #innovation

 

Exhibitions Linkedin HT2019